Takara Bio

Takara Bio Debt

Delisted

The Debt of Takara Bio (4974.T) as of Nov 3, 2026 is 1.10 B JPY. In the previous year, Debt was 968.00 M JPY — a change of 13.74% (higher).

Debt

1.10 BJPY

YoY

13.74%

Last updated:

In 2025, Takara Bio's total debt was 1.10 B JPY, a 13.74% change from the 968.00 M JPY total debt recorded in the previous year.

The Takara Bio Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
0.00 JPY
Jan 1, 2019
0.00 JPY
Jan 1, 2020
1.12 B JPY
Jan 1, 2021
1.14 B JPY
Jan 1, 2022
1.05 B JPY
Jan 1, 2023
972.00 M JPY
Jan 1, 2024
968.00 M JPY
Jan 1, 2025
1.10 B JPY
The Takara Bio Debt history
YEARDebtYoY
1.10 BJPY+13.74%
968.00 MJPY-0.41%
972.00 MJPY-7.16%
1.05 BJPY-8.24%
1.14 BJPY+1.88%
1.12 BJPY—
0.00JPY—
0.00JPY-100.00%
129.00 MJPY-33.51%
194.00 MJPY-18.14%
237.00 MJPY-34.89%
364.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Takara Bio Stock analysis

What does Takara Bio do? Takara Bio Inc is a Japanese biotechnology company that has been active in the medical and life science industry since its founding in 1967. The company is a strong player in the field of molecular biology and operates in several countries such as the USA, Europe, and Asia. Takara Bio Inc was established as an independent company in 1999, focusing exclusively on the production of molecular biology products. The company offers a wide range of products in the fields of research and diagnostics, including enzymes, PCR kits, vectors and plasmids, antibodies, proteins, and cell culture products. Takara Bio Inc is organized into two divisions: Life Science Research and Diagnostics. The Life Science Research division provides products and solutions for research and development in areas such as molecular biology, neuroscience, proteomics, and genomics. The Diagnostics division offers products and solutions for clinical diagnostics and drug development. Takara Bio Inc also specializes in the automation of molecular biology procedures and offers automated systems that can perform processes such as nucleic acid extraction, PCR, and sequencing. The company is committed to sustainability and environmental protection, adhering to strict environmental and quality standards in its production processes and implementing waste reduction and efficient resource utilization programs. Overall, Takara Bio Inc is a leading company in the field of molecular biology, offering a wide range of products and solutions for research and diagnostics, and has become a key player in the life science industry through its global expansion and ability to provide custom solutions. Takara Bio is one of the most popular companies on Eulerpool.

Debt Details

Understanding Takara Bio's Debt Structure

Takara Bio's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Takara Bio's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Takara Bio’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Takara Bio’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Takara Bio stock

Debt of Takara Bio is 1.10 B JPY in 2025.

Debt of Takara Bio changed from 968.00 M JPY to 1.10 B JPY, representing a 13.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Takara Bio since 2006 – with annual values, charts, and detailed analysis.

Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Takara Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Takara Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Takara Bio